The information on this page is for informational purposes only and does not constitute medical advice. Consult your genetic counselor or specialist physician for treatment decisions.

Biology of Young Lung Cancer Study: The YOUNG LUNG Study

Plain-language summary

This study examines the biology of lung cancer in patients diagnosed at a young age by collecting data and specimens. It enrolls people aged 45 or younger at diagnosis who have pathologically confirmed lung carcinoma (NSCLC or SCLC). It is a study with no assigned phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase
N/A
Status
Recruiting
Sponsor
Dana-Farber Cancer Institute
Intervention
Data and Specimen Collection
Start date
1/1/2023
Estimated completion
8/1/2027
Countries
United States

Related genes

Locations

  • Boston, United States
  • Boston, United States
  • Boston, United States
  • Boston, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Age 45 and under at lung cancer diagnosis
* Pathologically confirmed bronchogenic lung carcinoma (NSCLC or SCLC of any stage) at any treatment time point
* Provision of written informed consent
* Willingness to undergo no more than two (2) peripheral blood draws in a four (4) week period, with no more than 50 ml peripheral blood collected over eight (8) weeks
* Individuals under age 18 are eligible for study if they meet defined criteria; in addition, consent for participation must be given by a legal guardian or parent

Exclusion Criteria:

* Individuals who decline to sign consent
* Individuals who are unable to give consent or assent and are without a designated healthcare proxy
* Compromise of patient diagnosis or staging if tissue is used for research
This is not medical advice. Consult your specialist.
View the official record on ClinicalTrials.gov →